Compare LBRX & ASPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | ASPN |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 573.2M |
| IPO Year | 2025 | 2014 |
| Metric | LBRX | ASPN |
|---|---|---|
| Price | $23.82 | $3.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $49.00 | $13.00 |
| AVG Volume (30 Days) | 210.8K | ★ 1.4M |
| Earning Date | 06-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $352,852,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.36 | $2.80 |
| 52 Week High | $24.95 | $12.71 |
| Indicator | LBRX | ASPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 42.11 |
| Support Level | $20.65 | $2.98 |
| Resistance Level | $24.95 | $3.44 |
| Average True Range (ATR) | 1.85 | 0.21 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 89.58 | 18.23 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.